Researchers at Nagoya University have developed a redesigned iron-based photocatalyst that outperforms earlier models and reduces dependence on rare, expensive metals in advanced chemical synthesis — achieving a world first in the process.
The team, led by Professor Kazuaki Ishihara and Assistant Professor Shuhei Ohmura, published findings in the Journal of the American Chemical Society describing a catalyst system that cuts chiral ligand usage by two thirds compared to their previous 2023 design, while operating under energy-efficient blue LED light.
The Problem With Rare Metals
Photocatalysts — materials that absorb light to drive chemical reactions — are foundational tools in organic synthesis. Metals like ruthenium and iridium dominate the field, but both are scarce and costly. Iron presents an obvious alternative: abundant, cheap, and far less geopolitically sensitive.
The Nagoya team had already introduced an iron-based photocatalyst in 2023. The catch was efficiency. That earlier version required three chiral ligands per iron atom, but only one actually contributed to enantioselectivity — the property that controls the three-dimensional shape of the resulting molecule. The other two were essentially dead weight.
A Leaner, Smarter Design
The new catalyst addresses this directly. It pairs affordable achiral bidentate ligands with chiral ligands to form a specific iron(III) salt structure. Each type of ligand has a defined role: the chiral ligand steers the three-dimensional configuration of the product, while the achiral bidentate ligand boosts overall catalytic performance.
The result is a system that does more with less — fewer costly components, cleaner reaction conditions, and the same precise molecular control that made rare-metal catalysts attractive in the first place.
“The new catalyst design represents the definitive form of chiral iron(III) photoredox catalysts,” said Ohmura. “We believe this achievement marks a significant milestone in advancing iron-based photocatalysis.”
A Chemistry First: (+)-Heitziamide A
Using this system, the researchers completed the first-ever total asymmetric synthesis of (+)-heitziamide A, a natural compound found in medicinal plants and known to suppress respiratory bursts. While laboratory synthesis of heitziamide A had been reported before, its naturally occurring enantiomer — the specific mirror-image molecular form — had never been produced this way.
The key reaction was a highly controlled radical cation (4 + 2) cyclization, where two molecular components join to form a six-membered ring. This structural motif appears frequently in natural products relevant to drug development.
The team also noted that using the mirror-image version of the catalyst should enable production of (-)-heitziamide A, giving chemists selective access to both enantiomers from a single platform.
Implications for Drug Synthesis
“Achieving the first-ever asymmetric total synthesis of (+)-heitziamide A using this catalytic reaction is a remarkable accomplishment,” said Ishihara. “Several additional bioactive substances can be accessed through total synthesis, with enantioselective radical cation (4 + 2) cycloaddition serving as a key step.”
The practical upside is tangible. Complex pharmaceutical precursors that previously required rare metals and expensive reagents may now be accessible through iron and blue LEDs — materials and tools that are far easier to source and scale.
- Chiral ligand usage reduced by two thirds versus the 2023 design
- Operates under blue LED light, improving energy efficiency
- First total asymmetric synthesis of (+)-heitziamide A achieved
- Both enantiomers of heitziamide A now theoretically accessible
Photo by beuwy.com Alexander Pütter on Unsplash
This article is a curated summary based on third-party sources. Source: Read the original article
